PMC:7534795 / 1518-1728 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T23","span":{"begin":81,"end":86},"obj":"Chemical"},{"id":"T24","span":{"begin":97,"end":108},"obj":"Chemical"},{"id":"T25","span":{"begin":143,"end":148},"obj":"Chemical"},{"id":"T26","span":{"begin":162,"end":170},"obj":"Chemical"}],"attributes":[{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"}],"text":"uted to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management o"}

{"project":"LitCovid-PubTator","denotations":[{"id":"49","span":{"begin":77,"end":86},"obj":"Chemical"},{"id":"50","span":{"begin":139,"end":148},"obj":"Chemical"}],"attributes":[{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D015525"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D015525"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"uted to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management o"}